€62.90
This product ships to the EU, the US and Canada
Looking for LGD4033 for sale? (Ligandrol) at our store, you can easily buy LGD4033 online. LGD4033 is a popular "dry" SARM undergoing clinical research.
| Synonyms | Ligandrol | |
| Concentration | 10mg per ml | |
| Solvent | USP Grade Polyethylene Glycol 400 | |
| Molar Mass | 338.25 g/mol | |
| CAS | 1165910-22-4 | |
| Chemical Formula |
|
This product is for laboratory research purposes only and is not approved by the FDA for human use. LGD4033 IS NOT A DIETARY SUPPLEMENT.
By choosing to buy SARMs at our store Sarmful.com you are investing in the highest quality ingredients, that means minimum 98% (and often higher) pure compounds tested and certified by accredited US third party labs- visit out tests page for more info.
More benefits:
LGD 4033 is a selective androgen receptor modulator (SARM) that was initially discovered and developed over a decade ago and has been offered for sale as a medical research compound supplement. It has been shown to have anabolic androgenic activity in muscle tissue. LGD 4033 is a non-steroidal agent, meaning it does not contain the C-17 carbon atom found in steroids. LGD-4033 binds selectively to the androgen receptor and does not convert to estrogen unlike many anabolic steroids do.
LGD-4033, commonly also known as Ligandrol, is a third gen. non-steroidal SARM with a very high affinity for the androgen receptor (Ki of ~1 nM). To present, it is one of the most popular SARM on the market. Unlike testosterone which exerts anabolic effects by the same pathway, LGD4033 has very high selectivity for receptors in skeletal muscle, bone, and connective tissue, with minimal affinity for receptors in the prostate, scalp and skin, which is a similar property as other SARMs. It was originally developed by Ligand Pharmaceuticals to combat common conditions such as muscle wasting and osteoporosis without the virilizing side effects of anabolic steroids [1]. The same study shows that preclinical primate data demonstrated a significant quantity dependent increase in lean body mass for male and female monkeys during 13 weeks at either 0.6, 3, 15, or 75 MG/KG of bodyweight doses. Furthermore, 70% of the increased body mass was retained after a 4 week recovery period. Only the 75mg/kg group stopped testing after 48 days due to toxicity. The caveat though is that this quantity is substantially higher than the highest quantity administered in clinical trials [3].
One Phase 1 clinical trial with 76 males adult administered LGD-4033 orally at varying quantities showed a quantity dependent increase in lean body mass and was well tolerated by all 76 subjects for 21 days [1,2].
In a different Phase 2 clinical trials consisted of 120 subjects recovering from hip fracture surgery, a common condition ails the eldered, the subjects were given either a placebo, 0.5, 1, or 2mg LGD-4033 over 12 weeks. All quantities of LGD-4033 created notable increases in total lean body mass and subjects induced a quantity dependent lowering in mean fat mass. Subjects administered LGD4033 showed improvements in serum procollagen type 1 propeptide (s-P1NP), a marker of bone anabolism, and improvements in 6-minute walk distance as compared to the placebo control group. No significant side effects were noted in any of the study groups. Subjects were assessed 12 weeks after completion of the trial, at which they maintained the muscle mass that they had gained from the drug [3].
By choosing to buy SARMs at our store Sarmful.com you are investing in the highest quality ingredients, that means minimum 98% (and often higher) pure compounds tested and certified by accredited US third party labs- visit out tests page for more info.
More benefits:
LGD 4033 is an oral SARM that was discovered by Ligand Pharmaceuticals and trialed in the late 2000s and early 2010s for the treatment of osteoporosis and muscle wasting. It is currently under research and development for a wide range of potential use cases by Viking Therapeutics.
In animal clinical trials LGD 4033 has increased strength and lean muscle mass in subjects. It has also been shown the ability to speed up the muscle healing process, reduce body fat, and increase bone density in subjects. LGD 4033 is typically taken in pill form, and the effects can be seen within 2-4 weeks of starting supplementation[1,2,3].
Subjects may experience some minor side effects including headaches, nausea, dry mouth, and muscle pain.
The lack of conversion (that is common in anabolic steroids) means that there are nor virilization effects.
LGD 4033 is currently available for sale by research chemical companies. It is important to note that this compound is still in development, and is not yet approved for human use. As such, it should only be used by those who are qualified to do so and under controlled conditions.
LGD4 and LGD 4033 are the same product. LGD4 is just an updated name.
They are two comparable SARMs. Both profile as compounds that increase strength in subjects. LGD 4033 tends to be a more potent compound. LGD 4033 has a better safety track record in its animal clinical trials.
LGD 4033 is reasonably safe and well tolerated . The frequency of adverse events was similar between the placebo and any dose group when tested. The most common adverse events were headache, diarrhea, and nausea. No serious adverse events were reported. These results suggest that LGD 4033 is safe and well tolerated in healthy adults.
The half-life of LGD 4033 is quite prolonged, lasting 24 to 36 hours. This suggests that the drug should be administered only once per day to test subjects. The linear pharmacokinetics of LGD 4033 indicate that there is no need for a dose adjustment based on body weight or age.
There is a lot of ambiguity around LGD 4033 and there are many questions that commonly arise.
LGD 4033 is a selective androgen receptor modulator (SARM). Like most SARMs, it tends to have anabolic activity in bones and muscles and tends to combat withering bone density. In animal subjects, it also displays a robust selectivity for muscle versus prostate.
LGD-4033 binds to the androgen receptor (AR) with high affinity and selectivity, thereby inhibiting the production of testosterone. LGD 4033 also decreases the production of other hormones, so it is believed to disrupt hormonal signaling in the body.
Ostarine is significantly less suppressive than LGD 4033. the potential side effects caused by suppressed testosterone levels are less likely in Ostarine. Similarly, androgen deficiency is also less likely to occur with Ostarine.
Research and lab experiments show that the profile of LGD 4033 is fairly safe. Most studies show little statistical difference in side effects or long-term issues between placebo and test groups.
It is, but LGD 4033 is not currently approved by the FDA for human consumption.
Ligandrol is just another name for the LGD 4033 compound.
LGD 4033 is a SARM that continues to be heavily researched for its potential benefits in treating muscle wasting, obesity, and osteoporosis
SARMs should only be used under the direct supervision and direction of a trained and licensed medical doctor or a designated research authority. Sarmful strongly discourages the use of SARMs for performance enhancement in fields of various sports such as bodybuilding and achievement sports, etc.
S4 is an investigational compound still undergoing research and NOT yet FDA approved, nor it is a dietary supplement. Sarmful is solely a research chemical supplier specializing in sourcing and quality control. We are not medical doctors. Sarmful discourages strongly against “bro science” and peer consensus when making decisions about human health.
We do not encourage or condone consumer use of SARMs products, they are for research purposes only.
1. Basaria et al. The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men. The Journals of Gerontology: Series A, Volume 68, Issue 1, January 2013, Pages 87–95. https://pubmed.ncbi.nlm.nih.gov/22459616/
2. Fragkaki et al. Human in vivo metabolism study of LGD-4033. Drug Test Analysis. Drug Test Anal. 2018 Nov;10(11-12):1635-1645. doi: 10.1002/dta.2512. Epub 2018 Nov 8. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.2512
3. “Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture.” FierceBiotech. Questex LLC, 03 Nov. 2015. Web. 21 Nov. 2016.
€62.90
